

CEN TOGENE NV COM EUR0.12

ISIN: NL0014040206 WKN: N1976T109 Asset Class: **Stock**

Company

2024/07/16 22:00:00



Price

0.53 USD

Difference ▼ -1.85% (-0.01)



Contact Details

CEN TOGENE NV Tel: +49-381-80113400
 -- Fax: +381-80113401
 Am Strande 7 Web: <http://www.centogene.com>
 18055 Rostock E-mail: -

Company Profile

Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. It operates through the following segments: Pharmaceutical, Diagnostics, and Corporate. The Pharmaceutical segment provides solutions to pharmaceutical partners, including target discovery, early patient recruitment and identification, epidemiological insights, and biomarker discovery. The Diagnostics segment offers genetic sequencing and diagnostics services to clients, who are typically physicians, laboratories, or hospitals, either directly or through distributors. The Other segment covers COVID-19 testing services to clients. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	48,625,000		63,855,000		58,539,000	
Common stock capital		3,841,000		3,529,000		3,079,000
Fixed assets	36,603,000		35,197,000		44,597,000	
Equity capital of a company		-27,927,000		7,909,000		31,276,000
Cash and cash equivalents	21,097,000		38,368,000		20,262,000	
Accrued liabilities		435,000		277,000		0
Other assets	-		-		-	
Current liabilities		47,904,000		26,323,000		44,914,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		58,955,000		57,683,000		17,816,000
Different income		-		-		-
Other liabilities		320,000		616,000		0
Total assets	85,229,000	85,229,000	99,053,000	99,053,000	103,137,000	103,137,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	493	517	808
Equity ratio	-32.77%	7.98%	30.54%
Debt-equity ratio	-405.18%	1,152.35%	227.46%

Others

	2023	2022	2021
Tax Expense Rate	-0.82%	-0.28%	0.05%

CENTOGENE NV COM EUR0.12

ISIN: NL0014040206 WKN: N1976T109 Asset Class: **Stock**

Income statement

	2023	2022	2021
Turnover	52,473,000	49,892,000	224,485,000
Net income	-38,414,000	-40,675,000	-55,494,000
EBIT	-26,765,383	-33,816,907	-49,975,715
Operating income before taxes	-37,777,000	-40,563,000	-55,406,000
Cash Flow	-40,796,000	-32,997,000	-26,007,000
Net interest income	-8,640,000	-3,749,000	-1,002,000
Research and development expenses	11,221,000	15,303,000	18,198,000
Income taxes	310,000	112,000	-28,000
Result from investments in subsidiaries, associates and other	-326,000	0	0
Revenues per employee	97,772	88,649	255,213

Board of Directors

Peer Schatz	Chairman of Supervisory Board
Eric Sou�tre	Member of Supervisory Board
Hubert Birner	Member of Supervisory Board
Jonathan Sheldon	Member of Supervisory Board
Guido Prehn	Member of Supervisory Board
Mary Sheahan	Member of Supervisory Board

Members of Management Board

Kim Stratton	Chairman of Managing Board
Ian Rentsch	Member of Executive Committee
Miguel Coego Rios	Member of Executive Committee
Peter Bauer	Member of Executive Committee